Adrian et al compared the relationship between targetable genomic alterations and age in 2237 patients with lung cancer and found that young patients had higher frequencies of EGFR, ALK, ROS1, and ERBB2 alterations [9]. Here, ERBB2 is linked to lung carcinoma.